

ASX Release

Updated information

ArTiMistTM listed as one of the 5 most promising drugs in Phase III - full article

On 30 March 2011 Eastland announced that Thomson Reuters had listed Eastland's lead project ArTiMistTM as being one of the 5 most promising drugs to enter into Phase III trials. Included in the announcement, Eastland had provided a link to the article.

It has been brought to our attention that the link in the 30 March announcement is no longer valid. A copy of the full report can be accessed under Announcements News & Media Releases on the Eastland website.

The title of the report is "Thomson Reuters - ArTiMist $^{\text{TM}}$ listed as 1 of 5 most promising drugs".

The Eastland website address is: eastlandmedical.com.au

Further information:

Stephen Carter
Chief Executive Officer
Director
Eastland Medical Systems Ltd

Tel: +61 8 6142 5555

sjcarter@eastlandmedical.com.au